Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials
DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.
Autobahn’s elunetirom Fast Track win puts bipolar depression back in regulatory focus
Bipolar depression needs better options. Autobahn’s elunetirom Fast Track status raises the stakes for its Phase 2 readout.
How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy
Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.
Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability
Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.
What BioXcel Therapeutics’ latest BXCL501 milestone could mean for neuropsychiatric care
Find out how BioXcel Therapeutics’ BXCL501 study could reshape acute stress care and influence future neuropsychiatric treatment pathways.
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.